{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:04:53Z","timestamp":1790881493144,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.cmi.2025.04.045","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:11:47Z","timestamp":1746796307000},"page":"1272-1282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Connor","family":"Prosty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Noutsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke G.L.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrin","family":"Ghanem-Zoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim J.","family":"Kaasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Kouijzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan J.","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.C.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean W.X.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.04.045_bib1","article-title":"Incidence trends and epidemiology of Staphylococcus aureus bacteremia: a systematic review of population-based studies","volume":"14","author":"Hindy","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.cmi.2025.04.045_bib2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cmi.2022.03.015","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.045_bib3","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/cid\/ciad363","article-title":"Global differences in the management of Staphylococcus aureus bacteremia: No international standard of care","volume":"77","author":"Westgeest","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae069","article-title":"Clinical significance of cefazolin inoculum effect in serious MSSA infections: a systematic review","volume":"6","author":"Lo","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.cmi.2025.04.045_bib5","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cmi.2025.04.045_bib6","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cmi.2025.04.045_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","article-title":"Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy","volume":"67","author":"Gould","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26366","article-title":"Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines group consensus statement","volume":"6","author":"McDonald","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2025.04.045_bib9","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.045_bib10","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus network adaptive platform trial protocol: new tools for an old foe","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023151","article-title":"Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial","volume":"8","author":"Burdet","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2025.04.045_bib12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/archinte.1965.03870030020005","article-title":"Dicloxacillin. In vitro and pharmacologic comparisons with oxacillin and cloxacillin","volume":"116","author":"Gravenkemper","year":"1965","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2025.04.045_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archinte.1963.03860010067005","article-title":"New antistaphylococcal antibiotics. Comparative in vitro and in vivo activity of cephalothin, nafcillin, cloxacillin, oxacillin, and methicillin","volume":"112","author":"Sidell","year":"1963","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2025.04.045_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1086\/338047","article-title":"Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials","volume":"34","author":"Maraqa","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib15","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.03122-15","article-title":"Adverse events lead to drug discontinuation more commonly among patients who receive nafcillin than among those who receive oxacillin","volume":"60","author":"Viehman","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib16","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1093\/jac\/dky259","article-title":"Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins","volume":"73","author":"Bidell","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/bcp.13554","article-title":"Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia","volume":"84","author":"Rindone","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cmi.2025.04.045_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijantimicag.2018.11.013","article-title":"Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: results of a systematic review and meta-analysis","volume":"53","author":"Lee","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.045_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40121-019-00259-4","article-title":"Cefazolin versus anti-Staphylococcal penicillins for the treatment of patients with methicillin-susceptible Staphylococcus aureus infection: a meta-analysis with trial sequential analysis","volume":"8","author":"Allen","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.04.045_bib21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.045_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamasurg.2021.0522","article-title":"MOOSE reporting guidelines for meta-analyses of observational studies","volume":"156","author":"Brooke","year":"2021","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cmi.2025.04.045_bib23","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.training.cochrane.org\/handbook."},{"key":"10.1016\/j.cmi.2025.04.045_bib25","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.045_bib26","unstructured":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. In: McGuinness\u20142021\u2014Research Synthesis Methods. Wiley Online Library; n.d. https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jrsm.1411. Accessed June 28, 2024."},{"key":"10.1016\/j.cmi.2025.04.045_bib27","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 8AD;36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","DOI":"10.18637\/jss.v036.i03"},{"key":"10.1016\/j.cmi.2025.04.045_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","author":"Balduzzi","year":"2019","journal-title":"Evidence-Based Mental Health"},{"key":"10.1016\/j.cmi.2025.04.045_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trial."},{"key":"10.1016\/j.cmi.2025.04.045_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2025.04.045_bib31","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2025. Available from https:\/\/www.gradepro.org\/."},{"key":"10.1016\/j.cmi.2025.04.045_bib32","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s10096-021-04313-3","article-title":"Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study","volume":"40","author":"Lef\u00e8vre","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106363","article-title":"Clinical outcomes of daptomycin versus anti-Staphylococcal beta-lactams in definitive treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"58","author":"Agnello","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.045_bib34","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib35","doi-asserted-by":"crossref","first-page":"ofz270","DOI":"10.1093\/ofid\/ofz270","article-title":"Comparative effectiveness of exclusive exposure to nafcillin or oxacillin, cefazolin, piperacillin\/tazobactam, and fluoroquinolones among a national cohort of veterans with methicillin-susceptible Staphylococcus aureus bloodstream infection","volume":"6","author":"Beganovic","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000499033","article-title":"Does the beta-lactam matter? Nafcillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"63","author":"Burrelli","year":"2018","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2025.04.045_bib37","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ijantimicag.2018.02.013","article-title":"A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia","volume":"52","author":"Davis","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.045_bib38","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s10096-024-04851-6","article-title":"Effectiveness and safety of cefazolin versus cloxacillin in endocarditis due to methicillin-susceptible Staphylococcus spp.: a multicenter propensity weighted cohort study","volume":"43","author":"Destrem","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40121-017-0148-z","article-title":"The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"6","author":"Flynt","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2025.04.045_bib40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijid.2023.10.019","article-title":"Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort","volume":"137","author":"Herrera-Hidalgo","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00039-23","article-title":"Retrospective evaluation of the association of oxacillin MIC on acute treatment outcomes with cefazolin and antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"61","author":"Hess","year":"2023","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.04.045_bib42","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1055\/a-0653-7826","article-title":"Infektiologische Konsile bei Patienten mit Staphylococcus-aureus-Bakteri\u00e4mie\u2014eine retrospektive Beobachtungsstudie am Universit\u00e4tsklinikum Jena","volume":"143","author":"Kimmig","year":"2018","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.cmi.2025.04.045_bib43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmi.2017.07.001","article-title":"Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea","volume":"24","author":"Lee","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.045_bib44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.cmi.2020.08.044","article-title":"Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study","volume":"27","author":"Lecomte","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.045_bib45","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus Bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib46","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jmii.2018.07.006","article-title":"A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"53","author":"Miller","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.cmi.2025.04.045_bib49","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/jac\/dkad263","article-title":"Treatment outcomes with benzylpenicillin and non-benzylpenicillin antibiotics, and the performance of the penicillin zone-edge test versus molecular detection of blaZ in penicillin-susceptible Staphylococcus aureus (PSSA) bacteraemia","volume":"78","author":"Mok","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib50","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jiph.2018.02.004","article-title":"Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Monogue","year":"2018","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.cmi.2025.04.045_bib51","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.045_bib52","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","article-title":"Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a California tertiary medical center","volume":"60","author":"Pollett","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib53","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/AAC.04677-14","article-title":"Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"59","author":"Rao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib54","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1542-4758.2010.00507.x","article-title":"High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia","volume":"15","author":"Renaud","year":"2011","journal-title":"Hemodial Int"},{"key":"10.1016\/j.cmi.2025.04.045_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10096-021-04330-2","article-title":"Penicillin versus anti-staphylococcal beta-lactams for penicillin-susceptible Staphylococcus aureus blood stream infections: a retrospective cohort study","volume":"41","author":"Reynolds","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib56","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s15010-023-02168-8","article-title":"Flucloxacillin and cefazolin for treatment of Staphylococcus aureus bloodstream infection","volume":"52","author":"Schmidt-Hellerau","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2025.04.045_bib57","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/phar.2124","article-title":"Clinical outcomes with penicillin versus alternative \u03b2-lactams in the treatment of penicillin-susceptible Staphylococcus aureus bacteremia","volume":"38","author":"Shah","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2025.04.045_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjms.2020.04.006","article-title":"Comparison of nafcillin and cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia","volume":"360","author":"Twilla","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.cmi.2025.04.045_bib59","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/jac\/dkac152","article-title":"Empirical use of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study","volume":"77","author":"Willekens","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.045_bib60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s10096-023-04575-z","article-title":"Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia","volume":"42","author":"Yetmar","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.04.045_bib61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.045_bib62","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1093\/jac\/dkae318","article-title":"Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?","volume":"79","author":"Duke","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25002356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25002356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:02:52Z","timestamp":1768935772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25002356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1198743X25002356"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.045","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}